@article{bc5a76dcd7974ebfb812afd46c93754e,
title = "The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry",
abstract = "Background: Eribulin provided significant overall survival (OS) benefit in heavily pretreated advanced breast cancer patients in the EMBRACE trial. We investigated the use of eribulin in daily clinical practice, the relative effectiveness of eribulin versus non-eribulin chemotherapy, and the safety of eribulin in real-world patients included in the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Material and methods: Patients treated with eribulin and eligible patients for eribulin who received a different chemotherapy (i.e., non-eribulin group) in ten hospitals in 2013-2017 were included. A multivariate matching algorithm was applied to correct for differences in baseline characteristics between the groups, including the number of previous treatment lines. Progression-free survival (PFS) and OS of eribulin were compared with the matched non-eribulin group through Kaplan-Meier curves and multivariate Cox proportional hazard models. The occurrence of dose delay and reduction was described. Results: Forty-five patients received eribulin according to its registration criteria and 74 patients were eligible for eribulin but received non-eribulin chemotherapy. Matching increased the similarity in baseline characteristics between the eribulin and non-eribulin groups. Median PFS was 3.5 months (95% confidence interval (CI): 2.7-5.5) in the eribulin group and 3.2 months (95% CI: 2.0-4.8) in the matched non-eribulin group (adjusted hazard ratio (HR): 0.83, 95% CI: 0.49-1.38). Median OS was 5.9 months (95% CI: 4.6-11.0) and 5.2 months (95% CI: 4.6-9.5) in the eribulin and non-eribulin groups, respectively (adjusted HR: 0.66, 95% CI: 0.38-1.13). Dose delay or reduction occurred in 14 patients (31%) receiving eribulin. Conclusions: No difference in PFS and OS was observed between eribulin and non-eribulin treated patients. Eribulin had a manageable toxicity profile.",
keywords = "Eribulin, breast neoplasms, matching, genetic matching, relative effectiveness, EXPANDED ACCESS PROGRAM, EFFICACY, MESYLATE, SAFETY, CAPECITABINE, MONOTHERAPY, MULTICENTER, TOXICITY",
author = "Pouwels, {X. G. L. V.} and Geurts, {S. M. E.} and Ramaekers, {B. L. T.} and F. Erdkamp and Vriens, {B. E. P. J.} and Aaldering, {K. N. A.} and {van de Wouw}, {A. J.} and Dercksen, {M. W.} and Smilde, {T. J.} and Peters, {N. A. J. B.} and Riel, {J. M. van} and Pepels, {M. J.} and J. Heijnen-Mommers and Joore, {M. A.} and Tjan-Heijnen, {V. C. G.} and {de Boer}, M.",
note = "Funding Information: XP, BR, FE, BEPJV, AJvdW, MWD, TJS, NAJBP, JMGvR, MP, and JH-M do not have any conflict of interest to declare. KNAA reports participating in an advisory board concerning Halaven. SMEG reports grants from Novartis BV, grants from Roche, grants from Pfizer, grants from Netherlands Organization for Health Research and Development (ZonMw: 80-82500-98-8003), during the conduct of the study. MAJ reports grants from EISAI, during the conduct of the study; grants from Novartis, grants from Pfizer, grants from Roche, outside the submitted work. VCTH reports grants from Novartis, grants from Pfizer, grants from Roche, grants from EISAI, grants from AstraZeneca, grants and personal fees from Pfizer, Roche, Novartis, AstraZeneca, outside the submitted work. MdB reports grants from EISAI, during the conduct of the study; grants from Novartis, grants from Pfizer, grants from Roche, outside the submitted work. Data analysis and interpretation were performed without assistance of the funding sources. The publication of study results was not contingent on the sponsor{\textquoteright}s approval or censorship of the manuscript. Funding Information: The SONABRE Registry is supported by the Netherlands Organization for Health Research and Development (ZonMw: 80-82500-98-8003), Eisai, Novartis BV, Roche, Pfizer, and Eli Lilly and company. We thank all registration clerks of the SONABRE Registry for their involvement in the data collection process. Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2020",
month = jan,
day = "2",
doi = "10.1080/0284186X.2019.1670356",
language = "English",
volume = "59",
pages = "82--89",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Routledge/Taylor & Francis Group",
number = "1",
}